# UT SOUTHWESTERN MEDICAL CENTER: Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy

**Lab Budget Score:** 25/100

| Field | Value |
|---|---|
| Organization | UT SOUTHWESTERN MEDICAL CENTER |
| Location | DALLAS, TX |
| Project | Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy |
| Project number | 5K08CA267189-05 |
| Mechanism | K08 |
| Institute | National Cancer Institute |
| Award | $246,878 |
| Awarded | 2026-09-17 |
| Project period | 2022-09-13 to 2027-08-31 |
| UEI | YZJ6DKPM4W63 |

## Why this score
- Award of $246,878.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11398970). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.